Romosozumab Safely Restores Bone Mass in Multiple Myeloma via Osteoblast Reprogramming: A Phase IIa Study

Abstract excerpt

<h4>ABSTRACT</h4> Multiple myeloma causes devastating osteolytic bone disease. Current antiresorptive therapies slow bone loss but fail to rebuild the skeleton. Consequently, patients continue to fracture and suffer the associated morbidity and mortality. Targeting the Wnt inhibitor sclerostin, with romosozumab, increases bone mass in osteoporosis but has not been leveraged in cancer. We hypothesised that romosoz...

Topics

Open a Topic to create a Post that cites this publication.

• Bone and Bones
• Bone Density
• Disease Progression
• Fractures, Bone
• Histone Deacetylase Inhibitors Research
• Monoclonal Gammopathy of Undetermined Significance
• Multiple Myeloma
• Multiple Myeloma Research and Treatments

Identifiers and source

Literature Corpus work

6ef7f230-2b39-57c5-ac5b-810ea755b109

DOI

10.64898/2026.07.02.26357196